<DOC>
	<DOCNO>NCT02739880</DOCNO>
	<brief_summary>The main objective study measure change thickness vaginal lining ( epithelium + underlie stroma ) 0 8 week injection .</brief_summary>
	<brief_title>Multi-point Intra-mucosal Injections Cross-linked Hyaluronic Acid ( DESIRIAL® ) Vaginal Vestibule</brief_title>
	<detailed_description>The secondary objective study measure change follow 0 8 week injection : A. vaginal flora Nugent score . B. vaginal pH . C. functional evolution via VHI index Gloria Bachman ( state vaginal mucosa ) , pain / dyspareunia ( visual analog scale ) satisfaction concern care viay PGI-I questionnaire ( Patient Global Impression Improvement ) . D. Procollagen I III gene expression ( PCR ) mitotic activity mucosa ( Ki67 proliferation marker ) base biopsy .</detailed_description>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>The patient must give inform sign consent The patient must insure beneficiary health insurance plan The patient available 8 week followup The patient menopausal ( amenorrhea ) 2 year less 10 year The patient body mass index &lt; 35 The patient sexual disorder ( dyspareunia ) vaginal discomfort associate vaginal dryness . The patient participate another study The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient pregnant breastfeed The patient menopausal ( clinically biologically ) The patient body mass index &gt; 35 The patient genital prolapse high stage 2 surgical indication The patient stress incontinence surgical indication The patient suffers vaginismus Presence untreated viral , fungal bacterial vulvovaginal urinary infection Hemorrhagic neoplastic genital pathology Existence hormonedependent tumor , genital bleed unknown origin Current treatment base antihypertensive , steroid antiinflammatory drug , anticoagulant , major antidepressant , aspirin Known hypersensitivity hyaluronic acid mannitol Known hypersensitivity Betadine Known hypersensitivity Lidocaine Hypersensitivity EMLA® Previous urogynaecological vulvovaginal surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vaginal discomfort</keyword>
	<keyword>Vaginal dryness</keyword>
</DOC>